(Q41458688)

1 October 2017

1 reference

title

Effects of route and formulation on clinical pharmacokinetics of interleukin-2. (English)

1 reference

1 October 2017

1 reference

P M Anderson

1

1 reference

PubMed ID

7955769

1 October 2017

M A Sorenson

series ordinal

2

1 reference

1 October 2017

1 July 1994

1 reference

Clinical Pharmacokinetics

1 October 2017

1 reference

1 October 2017

27

1 reference

1 October 2017

19-31

1 reference

1 October 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199427010-00003

1 October 2017

0 references

cites work

Biodistribution and pharmacokinetics of recombinant, human 125I-interleukin-2 in mice

1 reference

12 December 2020

Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases

1 reference

12 December 2020

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

1 reference

12 December 2020

Preliminary clinical trial of immunotherapy for malignant glioma

1 reference

12 December 2020

The international standard for human interleukin-2. Calibration by international collaborative study.

1 reference

12 December 2020

Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration

1 reference

12 December 2020

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

12 December 2020

Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

1 reference

12 December 2020

Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution

1 reference

12 December 2020

Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

1 reference

12 December 2020

Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion

1 reference

12 December 2020

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

12 December 2020

T cell growth factor: parameters of production and a quantitative microassay for activity

1 reference

12 December 2020

Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen

1 reference

12 December 2020

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

12 December 2020

Recombinant interleukin-2: a biological response modifier

1 reference

12 December 2020

Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 recept

1 reference

12 December 2020

In vivo activity of solid phase interleukin 2

1 reference

12 December 2020

The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

12 December 2020

Relapse in the central nervous system in melanoma patients successfully treated with biomodulators

1 reference

12 December 2020

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

12 December 2020

Pharmacokinetics of recombinant interleukin-2 in children with malignancies: a Pediatric Oncology Group study

1 reference

12 December 2020

Long term culture of tumour-specific cytotoxic T cells

1 reference

12 December 2020

Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

1 reference

12 December 2020

Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients

1 reference

12 December 2020

Interleukin-2 toxicity

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells

1 reference

12 December 2020

Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.

1 reference

12 December 2020

Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study

1 reference

12 December 2020

Lowest dose interleukin-2 immunotherapy.

1 reference

12 December 2020

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience

1 reference

12 December 2020

Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Use of liposomes as injectable-drug delivery systems

1 reference

12 December 2020

Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2.

1 reference

12 December 2020

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

12 December 2020

Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report

1 reference

12 December 2020

Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2.

1 reference

12 December 2020

Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations

1 reference

12 December 2020

An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Reconstitution of interleukin 2 with albumin for infusion

1 reference

12 December 2020

The role of pharmacokinetics in the development of biotechnologically derived agents

1 reference

12 December 2020

Interleukins. Clinical pharmacokinetics and practical implications

1 reference

12 December 2020

Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration

1 reference

12 December 2020

Rational immunotherapy with interleukin 2

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

12 December 2020

Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases

1 reference

12 December 2020

Immunomodulators as local hormones: new insights regarding their clinical utilization

1 reference

12 December 2020

Enhancement of therapeutic effects of recombinant interleukin 2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, pluronic gel

1 reference

12 December 2020

Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro

1 reference

12 December 2020

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1 reference

12 December 2020

Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis

1 reference

12 December 2020

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

12 December 2020

Systemic biodistribution of radioiodinated interleukin-2 in the rat

1 reference

12 December 2020

Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration

1 reference

12 December 2020

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice

1 reference

12 December 2020

Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies

1 reference

12 December 2020

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

The importance of added albumin during continuous intravenous infusion of interleukin-2 with alpha-interferon

1 reference

12 December 2020

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

1 reference

12 December 2020

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

1 reference

12 December 2020

Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer

1 reference

12 December 2020

Role of the kidney in metabolic change of interleukin-2

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer

1 reference

12 December 2020

Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2

1 reference

12 December 2020

Interleukin-2 by Inhalation: Local Therapy for Metastatic Renal Cell Carcinoma

1 reference

12 December 2020

The fate of interleukin-2 after in vivo administration

1 reference

12 December 2020

A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.

1 reference

12 December 2020

A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.

1 reference

12 December 2020

10.2165/00003088-199427010-00003

Identifiers

DOI

1 reference

PubMed ID

7955769

Dimensions Publication ID

1 October 2017

0 references

1 reference

PubMed ID

7955769